Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Why Bristol Myers Squibb Is A Top Socially Responsible Dividend Stock
03:25pm, Monday, 10'th Jun 2024
Bristol Myers Squibb has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.8% yield, as w
7 Stocks Warren Buffett Has Sold in the Past Year (and You Should Too)
12:00pm, Monday, 10'th Jun 2024
The Oracle of Omaha is by far the most well-known long-term investor we have alive today, and if you are a newbie, looking into Warren Buffett stocks to sell is a good way to weed out the bad stocks f
Bristol Myers: Quality Fundamentals Suppressed By Interest Rates
03:34am, Sunday, 09'th Jun 2024
Bristol Myers Squibb has solid fundamentals that have been clouded by the rise of interest rates. The company's revenue is at risk due to higher debt burdens and future patent expiry concerns, but rec
The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024
09:00am, Saturday, 08'th Jun 2024
For many investors, especially those who are just building a portfolio, undervalued stocks under $50 hold significant appeal. Investors can start a significant position, in terms of shares owned, for
Dividend Harvesting Portfolio Week 170: $17,000 Allocated, $1,515.47 In Projected Dividends
09:00am, Thursday, 06'th Jun 2024
The Dividend Harvesting Portfolio generated over $100 of dividend income in May, with a return on invested capital of 14.14%. The portfolio's diversification helped stabilize market conditions, with a
I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastri
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)
03:11am, Wednesday, 05'th Jun 2024
Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo
02:21pm, Tuesday, 04'th Jun 2024
Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84%
09:00am, Tuesday, 04'th Jun 2024
Bristol-Myers Squibb has experienced significant declines in its stock price, but I believe it has potential for future growth. The risks of investing in BMY include underperformance compared to the m
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO24--Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or.
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
06:59am, Tuesday, 04'th Jun 2024
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference.
Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today
06:51pm, Monday, 03'rd Jun 2024
Bristol Myers Squibb (BMY) closed the most recent trading day at $41.77, moving +1.65% from the previous trading session.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS' Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
Earn An 'Embarrassing' Amount Of Cash Flow From These Contrarian Picks
08:10am, Monday, 03'rd Jun 2024
Amazon CEO Andy Jassy highlights key traits for success in a career professional, including working hard, being can-do, and following through on commitments. There are different paths to success, and
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations.
